scispace - formally typeset
Journal ArticleDOI

Clinical Application of Emerging Sensor Technologies in Diabetes Management: Consensus Guidelines for Continuous Glucose Monitoring (CGM)

Reads0
Chats0
TLDR
It is concluded that routine use of CGM, with real-time data showing the rate and direction of glucose change, could revolutionize current approaches to evaluating and managing glycemia.
Abstract
Continuous glucose monitoring (CGM) is an evolving technology poised to redefine current concepts of glycemic control and optimal diabetes management. To date, there are few randomized studies examining how to most effectively use this new tool. Therefore, a group of eight diabetes specialists heard presentations on continuous glucose sensor technology and then discussed their experience with CGM in order to identify fundamental considerations, objectives, and methods for applying this technology in clinical practice. The group concluded that routine use of CGM, with real-time data showing the rate and direction of glucose change, could revolutionize current approaches to evaluating and managing glycemia. The need for such progress is indicated by the growing prevalence of inadequately treated hyperglycemia. Coordinating financial and educational resources and developing clear protocols for using glucose sensor technology are urgent priorities in promoting wide adoption of CGM by patients and health care providers. Finally, researchers, manufacturers, payers, and advocacy groups must join forces on the policy level to create an environment conducive to managing continuous data, measuring outcomes, and formalizing best practices.

read more

Citations
More filters
Journal ArticleDOI

Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline

TL;DR: The practice of hypoglycemia risk factor reduction is recommended--addressing the issue of hypglycemia, applying the principles of intensive glycemic therapy, and considering both the conventional risk factors and those indicative of compromised defenses against falling plasma glucose concentrations--in persons with diabetes.
Journal ArticleDOI

Glucose sensors: a review of current and emerging technology

TL;DR: This review aims to summarize existing technology, the methods for assessing glucose sensing devices and provide an overview of emergent sensing modalities to become a critical component of the closed loop insulin delivery system.
Journal ArticleDOI

Artificial Pancreas: Past, Present, Future

TL;DR: The artificial pancreas (AP), known as closed-loop control of blood glucose in diabetes, is a system combining a glucose sensor, a control algorithm, and an insulin infusion device that has proved the feasibility of external glucose control and stimulated further technology development.
References
More filters
Journal ArticleDOI

Standards of medical care in diabetes.

David A. Power
- 01 Feb 2006 - 
TL;DR: I would like to take issue with the use of the phrase “standards of medical care in diabetes,” which is used to describe diabetes care standards, in the recently updated and circulatedADA 2006 Clinical Practice Recommendations.
Journal ArticleDOI

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

TL;DR: Intensive diabetes therapy has long-term beneficial effects on the risk of cardiovascular disease in patients with type 1 diabetes, and changes between treatment groups remained significant after adjusting for these factors.
Journal ArticleDOI

Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.

TL;DR: Glucose fluctuations during postprandial periods and, more generally, during glucose swings exhibited a more specific triggering effect on oxidative stress than chronic sustained hyperglycemia, suggesting that interventional trials in type 2 diabetes should target not only hemoglobin A1c and mean glucose concentrations but also acute glucose swings.
Journal ArticleDOI

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.

TL;DR: The reduction in the risk of progressive retinopathy and nephropathy resulting from intensive therapy in patients with type 1 diabetes persists for at least four years, despite increasing hyperglycemia.
Related Papers (5)